Search results

13 results for Alendronic acid

Sorted by Relevance . Sort by Date

  1. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults

  2. Osteoporosis

    Everything NICE has said on assessing the risk of, preventing and treating osteoporotic fragility fractures in adults in an interactive flowchart

  3. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

  4. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

  5. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women

  6. Multimorbidity

    Everything NICE has said on optimising care for people with 2 or more long-term health conditions in an interactive flowchart

  7. Medicines optimisation

    Everything NICE has said on shared decision-making and processes to optimise medicines and support adherence in an interactive flowchart

  8. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary hip fracture programme to help people recover faster and regain their mobility.

  9. Block scoping reports

    This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.